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Introduction: The PET tracer, 1-O-(4-(2-ﬂuoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-β-D-glucopyr-
onuronate ([18F]FEAnGA), was recently developed for PET imaging of extracellular β-glucuronidase (β-GUS).
However, [18F]FEAnGA exhibited rapid renal clearance, which resulted in a relatively low tracer uptake in the
tumor. To improve the pharmacokinetics of [18F]FEAnGA, we developed its more lipophilic methyl ester
analog, [18F]FEAnGA-Me.
Methods: [18F]FEAnGA-Me was obtained by alkylation of the O-protected glucuronide methyl ester precursor
with [18F]-ﬂuoroethylamine ([18F]FEA), followed by removal of the acetate protecting groups with NaOMe/
MeOH. The PET tracer was evaluated by in vitro and in vivo studies.
Results: [18F]FEAnGA-Me was obtained in 5%–10% overall radiochemical yield. It is 10-fold less hydrophilic than
[18F]FEAnGA and it is stable in PBS and in the presence of β-GUS for 1 h. However, in the presence of esterase or
plasma [18F]FEAnGA-Me is converted to [18F]FEAnGA, and subsequently converted to [18F]FEA by β-GUS.
MicroPET studies inWistar rats bearing a C6 glioma and a sterile inﬂammation showed similar uptake in tumors
after injection of either [18F]FEAnGA-Me or [18F]FEAnGA. Both tracers had a rapid two-phase clearance of total
plasma radioactivity with a half-life of 1 and 8 min. The [18F]FEAnGA fraction generated from [18F]FEAnGA-Me
by in vivo hydrolysis had a circulation half-life of 1 and 11 min in plasma. Similar distribution volume in the
viable part of the tumor was found after injection of either [18F]FEAnGA-Me or [18F]FEAnGA.
Conclusion: The imaging properties of [18F]FEAnGA-Me were not signiﬁcantly better than those of [18F]FEAnGA.
Therefore, other strategies should be applied in order to improve the kinetics of these tracers.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Glucuronide-drug conjugates exhibit lower toxicity towards
normal cells than the corresponding native drugs. However, glucuro-
nide-drug conjugates are susceptible to enzymatic cleavage by β-GUS,
resulting in the in situ generation of highly cytotoxic drugs. Since
tumors and inﬂammatory lesions have increased levels of β-GUS,
glucuronide conjugates have been investigated as tools to deliver
drugs to the target site.
For a better understanding of the mechanisms of action and
metabolic conversion of these prodrugs, we have recently synthesized
a radiopharmaceutical, 1-O-(4-(2-ﬂuoroethyl-carbamoyloxymethyl)-
2-nitrophenyl)-O-β-D-glucopyronuronate ([18F]FEAnGA), for non-
invasive PET imaging of extracellular β-GUS activity [1]. Micro-PET
with [18F]FEAnGA could clearly visualize enhanced β-GUS levels, inicine and Molecular Imaging,
ingen, 9700 RB Groningen, The
87.
es@yahoo.com (I.F. Antunes).
l rights reserved.particular in large tumors with necrotic areas, whereas uptake in
other organs was very low (except kidneys and bladder). The dis-
tribution volume (DVT) of [18F]FEAnGA in tumors correlatedwell with
the conversion of [18F]FEAnGA by the β-GUS enzyme. However,
because of the highly hydrophilic character of [18F]FEAnGA (logD=
−1.61), the PET tracer is very rapidly excreted via the kidneys into the
urine. This rapid renal clearance resulted in a relatively low absolute
tracer uptake in the tumor [2].
The disadvantage of rapid renal clearance was also found for
prodrugs such as DOX-GA3 and DNR-GA3 [3,4]. To reduce renal
clearance, de Graaf et al. converted DOX-GA3 to its methyl ester
(DOX-mGA3), which is substantially less hydrophilic [5]. The glucu-
ronide conjugate is negatively charged at physiological pH, whereas
the corresponding methyl ester is a neutral molecule. Slow release of
DOX-GA3 through conversion of its methyl ester by esterase activity
in blood resulted in a prolonged circulation half-life of DOX-GA3.
Intravenous administration of DOX-mGA3 in tumor bearing mice
resulted in a 2.7-fold increase in the delivery (area under the
concentration versus time curve (AUC) from 0.5 to 2 h) of doxorubicin
to the tumor, as compared to administration of DOX-GA3. Therefore,
855I.F. Antunes et al. / Nuclear Medicine and Biology 39 (2012) 854–863we hypothesized that a similar approach could increase the delivery
of [18F]FEAnGA as well. Therefore, we now synthesized its less
hydrophilic methyl ester of [18F]FEAnGA, called [18F]FEAnGA-Me.
When administered in vivo, the methyl group of [18F]FEAnGA-Me
should be removed by carboxylesterase activity in plasma to give the
original PET tracer [18F]FEAnGA, which could in turn be activated by
β-GUS at the target site (Scheme 1) and release 2-[18F]ﬂuoroethy-
lamine ([18F]FEA). The slow release of [18F]FEAnGA after adminis-
tration of [ 18F]FEAnGA-Me might result in improved
pharmacokinetics of the PET tracer in vivo, resulting in a higher
absolute tracer uptake in tumors.
In the present study, we describe the labeling of [18F]FEAnGA-Me
and its stability in vitro. In addition, we analyzed the in vitro
conversion of [18F]FEAnGA-Me to [18F]FEAnGA by esterase activity
and determined whether [18F]FEAnGA-Me could be converted to
[18F]FEAnGA and [18F]FEA in vivo. Finally, the PET imaging
characteristics of [18F]FEAnGA-Me were compared with the original
PET tracer [18F]FEAnGA.
2. Materials and methods
Reagents and solvents were obtained from commercial suppliers
(Sigma-Aldrich and Fluka, Zwijndrecht, the Netherlands and Merck,
Darmstadt, Germany) and used without further puriﬁcation. The
reference compounds, FEAnGA-Me and FEAnGA were prepared as
previously described [1]. For radiolabeled compounds, the detection
on the TLC was performed with Cyclone phosphor storage screens
(multisensitive, Packard, PerkinElmer Life and Analytica Science).
These screens were exposed to the TLC strips (60 s for in vitro
experiments and 20 min for in vivo experiments), subsequently read
out using a Cyclone phosphor storage imager (PerkinElmer) and
analyzed with OptiQuant software. HPLC puriﬁcations were per-
formed with an Elite LaChrom VWR Hitachi L-2130 pump system
using a Phenomenex Prodigy C18-column, connected to a UV-
spectrometer (Elite LaChrom VWR Hitachi L-2400 UV detector) set
at 254 nm and a Bicron frisk-tech radiation detector. Radioactivity
measurements for logD determination and cell studies were done
using an automated gamma counter (Compugamma, LKB Wallac).
Absorbance measurements in the enzyme assays were performed
with a UV-spectrophotometer (Waters 2487 dual wavelength absor-
bance detector).
2.1. Radiosynthesis of [18F]FEAnGA-Me (Scheme 2)
Aqueous [18F]ﬂuoride was produced via the 18O (p,n)18F nuclear
reaction by irradiation of [18O]water with a Scanditronix MC-17
cyclotron. The [18F]ﬂuoride solution was passed through an activated
SepPak Light Accell plus QMA anion exchange cartridge (Waters) to
recover the [18O]water. The [18F]ﬂuoride was eluted from the
cartridge with 1 mL of K2CO3 (5 mg/mL) and collected in a vial with
20 mg Kryptoﬁx[2.2.2.]. To this solution, 1 mL acetonitrile was addedScheme 1. General mechanism of aand the solvents were evaporated at 130 °C. The [18F]KF/Kryptoﬁx
complex was dried 3 times by the addition of 0.5 mL acetonitrile,
followed by evaporation of the solvent.
[18F]FEA was prepared by ﬂuorination of N-[2-(toluene-4-sulfo-
nyloxy)-ethyl]-phtalimide (30 mg, 0.09 mmol) in 500 μL of acetoni-
trile at 110 °C, followed by deprotection with hydrazine hydrate (50
μl, 1.03 mmol) as described in the literature [6]. The resulting amine
was distilled at 75 °C into an ice-cold solution of 1 (5 mg, 0.009mmol)
in acetonitrile (0.2 mL). The mixture was allowed to react at room
temperature for 30 min. The product was dried at 40 °C for 2 min
under a gentle argon ﬂow. Deprotection of the hydroxyl groups was
done by addition of 30 μL 0.5 M NAOMe/MeOH and incubation for
7 min at room temperature. The product was neutralized by the
addition of 20 μL 1 M AcOH, diluted with 2 mL of distilled water and
puriﬁed by HPLC using a semi-preparative Prodigy C18 reverse-phase
column (5 μ, 10×250mm; Phenomenex) with 17% ethanol in 0.025M
sodium phosphate buffer as the eluent (ﬂow rate, 4mL/min; retention
time: [18F]FEAnGA-Me=21 min; [18F]FEAnGA=6.4 min and [18F]
FEA=4.2 min). The radiolabeled compound [18F]FEAnGA-Me was
obtained in 5%–10% radiochemical yield from [18F]ﬂuoride (decay
corrected) in 120 min. Quality control was performed by HPLC with a
Symmetry C18 column [5 μm, 4.6×150 mm] with 15% acetonitrile in
sodium phosphate buffer 2.5 mM as the eluent (ﬂow rate, 1 mL/min;
retention time: [18F]FEAnGA-Me=14 min). The speciﬁc activity of
[18F]FEAnGA-Me was 185±71 GBq/μmol and the radiochemical
purity was always N95%. [18F]FEAnGA was prepared according to
the literature [2] with a speciﬁc activity of 149±33 GBq/μmol and the
radiochemical purity was always N95%.
2.2. Stability of [18F]EAnGA-Me
A sample of radiolabeled [18F]FEAnGA-Me was dissolved in PBS
(1 mL) and incubated at 37 °C. For 1 h, the stability of the radiolabeled
[18F]FEAnGA-Me was monitored by radio-TLC (Rf FEA=0.1, Rf
FEAnGA=0.4 and Rf FEAnGA-Me=1) (eluent: MeCN/H2O 7:3). After
elution, the TLC strips were analyzed by phosphor storage imaging. The
screens were scanned with Cyclone phosphor storage system (Perki-
nElmer) and the percentage of intact [18F]FEAnGA-Me as a function of
the incubation period was calculated by ROI analysis using OptiQuant
software. The experiment was performed in duplicate.
2.3. Distribution coefﬁcient (Log D7.4)
To determine the Log D7.4 of [18F]FEAnGA-Me an aliquot of 100 μL
of HPLC puriﬁed [18F]FEAnGA-Me solution was added to a mixture
of n-octanol/PBS (4 mL:4 mL) at pH 7.4. The tubes were vortexed at
room temperature for 30 s, followed by 30 min shaking in a water
bath at 37 °C. Aliquots of 1 mL were drawn from both the n-octanol
and aqueous phase. Radioactivity in both samples was counted
using an automated gamma counter. The experiments were per-
formed in triplicate.ctivation of the prodrug tracer.
Scheme 2. Radiosynthesis of compound [18F]FEAnGA-Me.
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To a solution of 0.1% bovine serum albumin (BSA), 200 μL (15U) of
carboxylesterase of porcine liver (Sigma-Aldrich) and/or 10 μL (74U)
Escherichia coli β-GUS (E. coli β-GUS) in 950 μL PBS (pH=7), 50 μL of a
0.004 M solution of FEAnGA-Me was added (total volume 1 mL). The
solutions were incubated in a water bath at 37 °C and 100 μL samples
were collected at different time points between 1 min and 60 min
after the start of incubation. The enzymatic activity was stopped by
dilution of the samples in 300 μL of acetonitrile and cooling of the
samples in ice. The release of 4-hydroxy-3-nitrobenzyl alcohol
(HNBA) (ɛ=3460 M−1 cm−1) was monitored by measuring the UV
absorbance at 412 nm. The experiment was performed in duplicate.
2.5. In vitro hydrolysis of [18F]FEAnGA-Me by plasma
To a 0.4 mL solution of PBS (pH=7.4), or rat plasma with or
without 10 μL (74U) Escherichia coli β-GUS, 0.1 mL of HPLC puriﬁed
[18F]FEAnGA-Me (2±0.2 MBq; 11±1 pmol) was added. The
solutions were incubated in a water bath at 37 °C and 2 μL samples
were collected at different time points between 30 s and 60 min after
the start of incubation. The degradation of the radiolabeled [18F]
FEAnGA-Mewas followed by radio-TLC (eluent: MeCN/H2O 7:3). After
elution, the TLCs were analyzed by phosphor storage imaging as
described above. The experiment was performed in duplicate.
2.6. Cellular uptake of [18F]FEAnGA-Me
C6 glioma cells weremaintained in 5mL Dulbecco'sModiﬁed Eagle
Medium (DMEM) supplemented with 7.5% fetal bovine serum (FBS)
in 25 cm3 culture ﬂasks. Cells were grown in a humidiﬁed atmosphere
containing 5% CO2 and were passaged every 3–4 days. For uptake
experiments, cells were plated in triplicate in a 12-well plate at a
density of 7×105 cells per well. After 24 h, the mediumwas discarded
and 1 mL of PBS-GMC buffer (5.6 mM D-glucose, 0.49 mM MgCl2 and0.68 mM CaCl2 in 100 mL phosphate-buffered saline (PBS)) per well
was added, followed by the addition of 200 μL [18F]FEAnGA-Me (ca.
250 kBq; ca. 1 pmol). In each series of 3 wells, either β-GUS (740 U),
esterase (15 U) or a combination of β-GUS (740 U) and esterase (15
U) was added. After 60 min of incubation at 37 °C, the medium was
collected, the cells washed with cold PBS (3×1 mL/well), harvested
with trypsin (250 μL) and resuspended in 1750 μL of DMEM (total
volume 2 mL/well). The cell suspensions and the medium were
collected separately for each well and the radioactivity was mea-
sured using a gamma counter. For each well, the medium was
analyzed for conversion of [18F]FEAnGA-Me to [18F]FEA by radio-TLC
as described above.
2.7. Animal model
Wistar rats (6–8 weeks old) were obtained from Harlan (Lelystad,
the Netherlands). The animals were provided with standard labora-
tory chow and tap water ad libitum. All studies were carried out in
compliance with the local ethical guidelines for animal experiments.
The protocols were approved by the Animal Ethics Committee of
University of Groningen. The tumor-inﬂammation model was de-
scribed previously [7,8]. Brieﬂy, C6 glioma cells [2–3×106 cells in a
1:1 mixture of Matrigel and Dulbecco's minimal essential medium
containing 7.5% fetal bovine serum] were subcutaneously injected
into the right shoulder of male Wistar rats. At day 12, 0.1 mL of
turpentine was intramuscularly injected into the thigh of the left hind
leg of the same animal.
2.8. PET imaging and ex vivo biodistribution studies
In the tumor-inﬂammation model (n=14), PET scans were per-
formed on day 13 after inoculation. The rats were anesthetized with
2% isoﬂurane (5% induction, 2% maintenance; Pharmachemie BV, the
Netherlands) and positioned in the small animal PET camera
(Siemens, Focus 220) with the tumor in the ﬁeld of view. Owing to
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to obtain a whole body scan of the rat. Although the camera is
equipped with a continuous bed motion option, this method is not
suitable to obtain quantitative information, because attenuation
correction is not feasible in this mode and the bed motion is
relatively slow with respect to tracer kinetics, especially at the early
time points. Moreover, imaging of the inﬂammatory lesions in the
leg is difﬁcult due to artifacts created by the high uptake in bladder,
which would also be in the ﬁeld-of-view. For the above mentioned
reasons the PET scan was only performed in the tumor region. A
transmission scan of 515 s with a Co-57 point source was obtained
for the correction of attenuation and scatter by tissue. After the
transmission scan was completed, [18F]FEAnGA-Me (8.6±0.7 MBq;
46±4 pmol) or [18F]FEAnGA (12.5±2.2 MBq; 84±5 pmol) was
injected via the penile vein. Simultaneously with the injection of the
PET tracer, an emission scan of 60 min was started. After completion
of the emission scan, the rats were sacriﬁced by extirpation of the
heart, while still being under deep isoﬂurane anesthesia. Several
tissues, peripheral organs, tumor and inﬂamed muscle were excised
and blood was collected. Plasma and red blood cells were obtained
from the blood sample by centrifugation (20 min at 6000 g). All
tissue samples and plasma were weighed and the amount of
radioactivity was determined with a gamma counter (LKB Wallac,
Turku, Finland). Tracer uptake is expressed as standardized uptake
value (SUV), which is deﬁned as: [tissue activity concentration
(MBq/g)×body weight (g) / injected dose (MBq)]. It was assumed
that 1 cm3 of tissue equals 1 g.
2.9. Pharmacokinetics studies
Wistar rats (n=22) bearing a C6 tumor were anesthetized with
isoﬂurane (5% induction, 2% maintenance) and a canula was inserted
into the femoral artery for collection of blood samples. Animals were
placed in the PET camera with the tumor in the center of the ﬁeld of
view. Simultaneously with the injection of either [18F]FEAnGA-Me
(7.0±0.9 MBq; 38±5 pmol) or [18F]FEAnGA (7.4±0.5 MBq; 50±3
pmol), a dynamic PET scan was started as described above. During the
60 min PET scan, blood samples of 100 μL were taken at 15, 30, 45, 60,
75, 90, 120, 150, 300, 450, 600, 1800, 3600 s after tracer injection.
After a blood sample was taken, 100 μL of heparinized saline was
injected via the artery canula to prevent large changes in blood
pressure. The blood samples were centrifuged at 6000 rpm for 10 min
and 50 μL of plasma was collected. The activity in plasma was
measured with a gamma counter (LKB Wallac, Turku, Finland). The
plasma–activity curves were corrected for decay. The rats were
sacriﬁced after the scans and the tumors were excised and weighed.
The radioactivity in the tumors was measured with a gamma counter
and converted to SUV.
2.10. PET image analysis
The list mode data of the emission scans were separated into 17
frames. Emission sinograms were iteratively reconstructed (OSEM2D,
4 iterations, 16 subsets) after being normalized, corrected for
attenuation, and corrected for radioactive decay. Three-dimensional
regions of interest (3D-ROIs) were generated automatically using the
intensity threshold method from Inveon Research Workplace soft-
ware package (Inveon, Siemens, USA) [9,10]. Brieﬂy, the last 9 frames
(10–60 min) were summed and an ROI of the viable part of the tumor
was generated automatically with a 50% threshold using a region
growing method, i.e. only pixels with tracer uptake greater than 50%
of the maximum value within the lesion were included. The resulting
ROIs were used on the original data set to create the corresponding 0–
60 min time–activity curves (TACs). A second ROI was drawn around
the whole tumor to obtain the total tumor volume (Vt; cm3), using
standard software (Inveon, Siemens, USA). In those animals whereplasma input curves were obtained through arterial sampling,
pharmacokinetic modeling of the tissue TACs was performed using
standard software (Inveon, Siemens, USA). The graphical Loganmodel
was used to determine the distribution volume, DVT, and a 2 tissue-
compartment model ﬁt was used to calculate the rate constants K1-k4
using a free blood volume.
2.11. Metabolite analysis
2.5 μL of each plasma sample was collected, applied on a TLC plate
(Merck F-254 silica gel) and eluted with acetonitrile/water (7:3).
After elution, TLC plates were analyzed by phosphor storage imaging.
Exposed screens were scanned with a Cyclone phosphor storage
system (PerkinElmer Life and Analytica Science) and the percentage
of conversion of [18F]FEAnGA-Me as a function of time was calculated
by ROI analysis using OptiQuant software.
2.12. Conversion of [18F]FEAnGA-Me to [18F]FEA with the release of
HNBA (Scheme 1)
Part of the tumors (containing both the rim and the necrotic core,
0.12±0.04 g) excised from the sampled animals was homogenized in
2 mL of phosphate buffered saline (PBS). The homogenates were
centrifuged (10 min, 3000 rpm, 4 °C) and the supernatant was
collected and kept on ice. To the supernatant, 2 mL of cold acetonitrile
was added to precipitate the remaining proteins. The samples were
vortexed for 30 s and centrifuged at 3000 rpm for 10 min at 4 °C. A
volume of 1.5 mL of the supernatant was added to 1.5 mL of cold
NaOH 0.25 M and UV absorption was measured (Waters 2487 dual
wavelength absorbance detector, 412 nm, aufs=0.01). Absorption
was converted in the concentration of HNBA, using a calibration curve.
The absorption was corrected for the weight (mg) of the tumor
sample. The measurements were performed in duplicate.
2.13. Statistical analysis
Statistical analyses were performed using Microsoft Excel 2003
and SigmaPlot (version 10.0; SPSS, Inc.). Differences in tumor
accumulation between tracers were analyzed using the two-sided
unpaired Student's t test. Differences in tracer accumulation between
inﬂamed and healthy muscle were studied in the same animal to
reduce variability between animals and therefore were analyzed
using the two-sided paired Student's t test. Signiﬁcance was reached
when the P value was b .05. Correlations were calculated with the
linear regression algorithm in SigmaPlot and were considered
statistically signiﬁcant whenever R2N0.5 and Pb .05. Throughout the
manuscript values are presented as mean±SEM.
3. Results
3.1. Labeling of [18F]FEAnGA-Me
[18F]FEAnGA-Me was prepared in analogy to [18F]FEAnGA, by the
reaction of [18F]FEA 2with the imidazolyl intermediate 1, followed by
removal of the acetate protecting groups with NaOMe/MeOH in
anhydrous conditions. [18F]FEAnGA-Me was obtained in a 10%±5%
overall radiochemical yield (corrected for decay, based on [18F]
ﬂuoride) with a total synthesis time of 120 min (Scheme 2). In
addition, approximately equal amounts of fully hydrolyzed [18F]
FEAnGA were formed.
3.2. Properties of [18F]FEAnGA-Me
The stability of [18F]FEAnGA-Me in PBS, was evaluated at 37 °C.
After 1 h of incubation, radio-TLC analysis showed that 95% of the
tracer was still intact while 5% was hydrolyzed to [18F]FEAnGA. We
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n-octanol/water distribution coefﬁcient (LogD) at pH 7.4. The logD of
[18F]FEAnGA-Me was found to be −0.58±0.0002.
3.3. In vitro hydrolysis of FEAnGA-Me/[18F]FEAnGA-Me
The enzymatic processing of FEAnGA-Me was ﬁrst studied using
commercially available bacterial Escherichia coli β-GUS and porcine
liver carboxylesterase. Fig. 1 indicates that incubation of FEAnGA-Me
with the combination of esterase and E. coli β-GUS resulted in 80%
conversion to FEA and 4-hydroxy-3-nitrobenzyl alcohol (HNBA),
while in the presence of E. coli β-GUS alone, only 6% of FEAnGA-Me
was converted to FEA and HNBA. This 6% conversion of FEAnGA-Me to
FEAnGA in the absence of esterase was probably due to some
spontaneous hydrolysis of the ester to the carboxylic acid. The
liberation of 4-hydroxy-3-nitrobenzyl alcohol (HNBA) was measured
by UV-spectrophotometry at 412 nm.
However, monitoring of the conversion of FEAnGA-Me to
FEAnGA was not possible, since neither glucuronide shows UV
absorption at this wavelength. Furthermore, we aimed to demon-
strate that esterases in plasma are able to hydrolyze the glucuronide
ester to the carboxylic acid. Therefore, we continued the hydrolysis
analysis with the radioactive compound, [18F]FEAnGA-Me. Radi-
olabeled [18F]FEAnGA-Me was incubated in rat plasma. After 30 min,
99% of [18F]FEAnGA-Me was converted to [18F]FEAnGA, while no
[18F]FEAnGA was generated in 0.1% BSA in PBS. When [18F]FEAnGA-
Me was incubated in rat plasma supplemented with E. coli β-GUS,
50% cleavage of the tracer to [18F]FEA was observed within 30 min
(Fig. 2).
3.4. Cellular uptake of [18F]FEAnGA-Me in C6 glioma cells
As depicted in Fig. 3, the cell-associated radioactivity was sig-
niﬁcantly increased by 60%, when C6 cells were incubated with [18F]
FEAnGA-Me in the presence of both E. coli β-GUS and esterase. After
incubation of C6 cells with [18F]FEAnGA-Me, cell-associated activity
was not affected by either E. coli β-GUS or esterase alone.
Furthermore, the radio-TLC analysis of the medium showed that in
the presence of both E. coli β-GUS and esterase the conversion of
[18F]FEAnGA-Me to [18F]FEA was 99%, while in the presence of E. coli
β-GUS alone there was only 7% of conversion to [18F]FEA. These
results suggest that the increase in cell associated radioactivity isFig. 1. In vitro release of the spacer HNBA from FEAnGA-Me and its quantiﬁcation by UV
absorption due to its yellow color (412 nm). FEAnGA-Me was exposed to either
esterase or E. coli β-GUS alone, or a combination of both enzymes.related with the conversion of [18F]FEAnGA-Me to [18F]FEA. The
latter compound is thought to have a higher tendency to associate to
the cells [1,2].
3.5. In vivo hydrolysis of [18F]FEAnGA-Me
The hydrolysis of [18F]FEAnGA-Me to [18F]FEAnGA by plasma was
also studied in tumor bearing rats. After injection into the rat, the
fraction of [18F]FEAnGA-Me present in plasma decreased rapidly to
50% in the ﬁrst 2 min, followed by a plateau phase. After 10 min, [18F]
FEAnGA-Me was more slowly converted to [18F]FEAnGA, with still
26% of the radioactivity in plasma being [18F]FEAnGA-Me at the end of
the study (60 min) (Fig. 4A). The fractions of radioactivity in plasma
consisting of [18F]FEAnGA and [18F]FEA reached their maximum
60min post injection (64% and 10%, respectively). When [18F]FEAnGA
was injected (Fig. 4B) only 12% was metabolized to [18F]FEA, which is
comparable to the amount of this compound found after injection of
the methyl ester.
The plasma activity curves of [18F]FEAnGA-Me, [18F]FEAnGA and
the [18F]FEAnGA fraction generated by in vivo hydrolysis of [18F]
FEAnGA-Me are shown in Fig. 5. Exponential curve-ﬁtting analysis
of [18F]FEAnGA-Me clearance showed a two-phase clearance with
25% of the injected activity having a half-life (t1/2)1 of 1±0.1 min
and 75% of the injected activity having a half-life (t1/2)2 of 8±1 min
(n=8), which are similar to the plasma clearance of [18F]FEAnGA
(27% (t1/2)1=1±0.1 min and 73% (t1/2)2=8±0.8 min, n=14). In
addition, the [18F]FEAnGA fraction generated in vivo by hydrolysis
of [18F]FEAnGA-Me (18% with (t1/2)1=1±0.2 min and 82% with
(t1/2)2=11±2 min (n=8)) had similar plasma clearance as [18F]
FEAnGA itself.
The AUC (1–60 min) of [18F]FEAnGA-Me (3.5±0.4) in plasma is
similar to the AUC of [18F]FEAnGA (3.3±0.3), whereas the AUC of the
[18F]FEAnGA fraction generated in vivo by hydrolysis of [18F]FEAnGA-
Me (2.3±0.5) was lower than the AUC of [18F]FEAnGA (3.3±0.3)
itself, although this difference was not statistically signiﬁcant.
3.6. PET study and ex vivo biodistribution
To test the potential of [18F]FEAnGA-Me as a PET tracer for
detecting β-GUS activity in vivo, a PET study was performed in rats
bearing a C6 glioma and sterile inﬂammation. A microPET scan was
performed in these rats after injection of either [18F]FEAnGA-Me
(n=6) or [18F]FEAnGA (n=8), in order to compare both tracers.
In the PET images (summed from 10 to 60 min, Fig. 6), [18F]
FEAnGA-Me showed a higher background activity when compared
to [18F]FEAnGA.
However, the time activity curves of [18F]FEAnGA-Me and [18F]
FEAnGA in tumors were similar (Fig. 6). The accumulation of
radioactivity in the viable part of the tumors after [18F]FEAnGA-Me
injection reached a maximum at 1.5 min post injection and
afterwards decreased exponentially with a half-life of 16±2 min,
while after [18F]FEAnGA injection, the accumulation of radioactivity
in the viable part of the tumors decreased with a half-life of
24±9 min (Fig. 6). In addition, the area under the curve (AUC) of
[18F]FEAnGA-Me in tumors (23±6) was similar to the AUC of [18F]
FEAnGA in tumors (20±4, P=.65).
To compare the distribution after [18F]FEAnGA-Me or [18F]FEAnGA
injection, ex vivo biodistribution studies of both tracers were
performed after the PET scan, i.e. at 60 min post injection. After
injection of [18F]FEAnGA-Me the uptake (SUV) in most of the
peripheral organs was similar to the uptake in these organs after
injection of [18F]FEAnGA. However, uptake in the liver and kidneys
was 3 times higher after injection of [18F]FEAnGA-Me than after
injection of [18F]FEAnGA (Pb .05) (Table 1). In the excised C6 tumors
(2.35±0.42 g), the uptake (SUV) was 0.13±0.02 at 1 h after injection
of [18F]FEAnGA-Me, while tracer uptake was 0.13±0.05 and
Fig. 2. Conversion of [18F]FEAnGA-Me in: PBS (top left side), PBS with E. coli β-GUS (top right side), rat plasma (bottom left side) and rat plasma with E. coli β-GUS (bottom right side).
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injected with [18F]FEAnGA the uptake was 0.13±0.03 in the excised
tumors (2.35±0.65 g) and 0.07±0.02 and 0.04±0.01 in the inﬂamed
and healthy muscles, respectively. The inﬂammation-to-muscle ratiosFig. 3. A) Cell associated radioactivity of [18F]FEAnGA-Me in control C6 cells and in C6 cells in
of cells presented in mean values of triplicate samples±SEM. ⁎⁎Pb .005, unpaired bidirectioof both tracers [18F]FEAnGA-Me (1.48±0.22) and [18F]FEAnGA
(1.59±0.19) were not signiﬁcantly different, but the tumor-to-
muscle ratios of [18F]FEAnGA-Me (1.85±0.23) were signiﬁcantly
lower than those of [18F]FEAnGA (3.53±0.52, P=.02).the presence of E. coli β-GUS and/or esterase. Data are expressed as % uptake per million
nal Student's t test. B) Radio-TLC of medium samples of C6 cells.
Fig. 4. Percentage of [18F]FEAnGA-Me, [18F]FEAnGA and [18F]FEA in the plasma of rats at different time points after injection of [18F]FEAnGA-Me (left, n=8) or [18F]FEAnGA (right,
n=14).
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The sampled rats were divided in two groups (injected with either
[18F]FEAnGA-Me or [18F]FEAnGA) to compare the tracers' pharmaco-
kinetics in vivo.
By applying 50% of SUVmax as the threshold, an ROI was obtained
representing the viable part of the tumor. The TACs of the viable part
of the tumor together with individual plasma radioactivity curves,
Logan graphical analysis and a 2 tissue reversible compartment model
were used for pharmacokinetic modeling.
The tumor distribution volume, DVT, from the Logan graphical
analysis after [18F]FEAnGA-Me injection (0.61±0.06), was not
signiﬁcantly different from the DVT after [18F]FEAnGA injection
(0.50±0.04). Similar distribution volumes were also obtained using
the 2 tissue compartment modeling (Table 2).
3.8. Measurement of β-GUS activity
β-GUS activity was assessed by measurement of the release of
HNBA from [18F]FEAnGA-Me or [18F]FEAnGA. β-GUS activity was
analyzed in homogenates of excised whole tumors. The conversion ofFig. 5. The time activity curves of [18F]FEAnGA-Me and [18F]FEAnGA in plasma as a
result of the i.v. administration of either [18F]FEAnGA-Me or [18F]FEAnGA.[18F]FEAnGA to [18F]FEA and HNBA in tumors was found to be similar
whether injected with [18F]FEAnGA-Me (0.35±0.08 [HNBA]/mg of
tissue) or [18F]FEAnGA (0.35±0.03 [HNBA]/mg of tissue).
4. Discussion
In the last years, interest into the development of radiolabeled
markers for the non-invasive evaluation of prodrug-converting
enzymes in solid tumors has increased [11–15]. Knowledge of the
prodrug-converting enzyme expression and activity can lead to a
better understanding of the mechanism of action and metabolic
conversion of the prodrug and could identify sites that are prone to
possible side-effects. Eventually, a suitable PET method might allow
the selection of patients eligible for β-GUS mediated prodrug therapy.
[18F]FEAnGA is a PET tracer capable of detecting increased release of
β-GUS in large solid tumors as well as in inﬂammatory lesions.
However, the renal clearance of [18F]FEAnGA was fast relative to the
conversion of [18F]FEAnGA to [18F]FEA resulting in a relatively low
tracer uptake in the tumor. Therefore, we synthesized the more
lipophilic methyl ester of [18F]FEAnGA, called [18F]FEAnGA-Me and
hypothesized that the increase in lipophilicity would prolong the
circulation half-life of the tracer which would result in prolonged
availability of the tracer for conversion by β-GUS.
The synthesis of [18F]FEAnGA-Me was similar to [18F]FEAnGA,
only differing in the deprotection process where NaOMe/MeOH in
anhydrous conditions was used instead of aqueous NaOH. This last
step was of critical importance with regards to the ﬁnal yield. In the
presence of acetonitrile and NaOMe/MeOH the major compound
obtained was [18F]FEAnGA. However, if compound [18F]-2 was dried
before adding NaOMe/MeOH, [18F]FEAnGA-Me was obtained in 5% to
10% yield. In addition, [18F]FEAnGA was concomitantly formed in
5%–10% yield. Despite numerous attempts to improve the ﬁnal yield,
we were not able to improve the yield any further. Thus, the ﬁnal
product [18F]FEAnGA-Me was obtained in 5%–10% overall radio-
chemical yield (corrected for decay, based on [18F]ﬂuoride) with a
total synthesis time of 120 min (Scheme 2). The identity of [18F]
FEAnGA-Me was conﬁrmed by coelution with a sample of the
nonradioactive compound by RP-HPLC. [18F]FEAnGA-Me was found
to be completely stable in PBS for at least 1 h.
We anticipated that the methyl group of [18F]FEAnGA-Me could be
enzymatically converted to the carboxylic acid of [18F]FEAnGA by
esterase in the blood (Scheme 1). Indeed, we showed that [18F]
FEAnGA-Me was completely hydrolyzed to [18F]FEAnGA in the
Fig. 6. Coronal microPET image of a rat injected with either [18F]FEAnGA-Me or [18F]FEAnGA on day 13 after inoculation of C6 cells (right side). Time activity curves of the tracer
uptake (SUV) in the viable part of C6 gliomas after injection with either [18F]FEAnGA-Me or [18F]FEAnGA (left side).
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[18F]FEAnGA-Me itself was not a substrate of E. coli β-GUS. However,
only after removal of the methyl group by esterase could complete
conversion of the resulting [18F]FEAnGA to [18F]FEA be achieved by E.
coli β-GUS. This result indicates that the activation of [18F]FEAnGA-Me
is a two-step process that requires both esterase and glucuronidase.
In vitro accumulation of [18F]FEAnGA-Me was investigated in C6
glioma cells. The cell-associated radioactivity derived from [18F]
FEAnGA-Mewas only increased in the presence of both esterase and E.
coli β-GUS. There is no signiﬁcant difference in the cell-associated
radioactivity of cells incubated with [18F]FEAnGA-Me alone or in the
presence of either E. coli β-GUS or esterase. The radio-TLC analysis of
the medium conﬁrmed that this increase in cell uptake is associated
with the conversion of [18F]FEAnGA-Me to [18F]FEA, since complete
conversion of the tracer to [18F]FEA was only observed when both
esterase and β-GUS were present. C6 cells incubated with [18F]
FEAnGA-Me, in the presence of both esterase and E. coli β-GUS
showed similar accumulation of radioactivity as C6 cells incubated
with [18F]FEA itself (0.8%) [2]. and 2 times higher uptake when
compared to C6 cells incubated with [18F]FEAnGA, in the presence of
E. coli β-GUS (0.4%). However, the cellular uptake of [18F]FEAnGA-MeTable 1
Ex vivo biodistribution 60 min p.i. of [18F]-FEAnGA-Me or [18F]FEAnGA in Wistar rats
bearing a C6 tumor and a sterile inﬂammation.











Red blood cells 0.07±0.02 0.06±0.01
Muscle, control 0.08±0.02 0.04±0.01
Muscle, inﬂamed 0.13±0.05 0.07±0.02⁎⁎
Tumor 0.13±0.02⁎⁎ 0.13±0.03⁎⁎⁎
Tracer uptake is expressed as standardized uptake values (SUV; mean±SEM). ⁎Pb .05
[18F]FEAnGA-Me when compared to [18F]FEAnGA; ⁎⁎Pb .05 and ⁎⁎⁎Pb .005 when
compared to control muscle.in control C6 cells (absence of enzymes) was also higher than the
uptake of [18F]FEAnGA, suggesting a lower in vitro selectivity of [18F]
FEAnGA-Me when compared to [18F]FEAnGA (Fig. 7).
As expected the lipophilicity of [18F]FEAnGA-Me was found to be
10 fold higher than [18F]FEAnGA. By analogy with the methyl ester
DOX-mGA3 which was 3 times less hydrophilic than the original
prodrug DOX-GA3, we hypothesized that the administration of the
less hydrophilic [18F]FEAnGA-Me would also result in a prolonged
circulation of [18F]FEAnGA in rats as compared to direct administra-
tion of the highly hydrophilic [18F]FEAnGA.
Houba et al. found that the administration of methyl ester DOX-
mGA3 in mice resulted in slow conversion of DOX-mGA3 to the
original DOX-GA3 in plasma, resulting in slower plasma clearance and
consequently, increased delivery and a higher concentration of DOX at
the target site. In contrast to the encouraging results by Houba et al.,
we did not ﬁnd any increase in radioactivity accumulation in the
tumor after administration of the methyl ester PET tracer [18F]
FEAnGA-Me, when compared to the original tracer [18F]FEAnGA. This
apparent discrepancy could be explained by differences in the
administered dose between the prodrug DOX-mGA (20,000 μg/kg)
and the PET tracer [18F]FEAnGA-Me (0.7 μg/kg). Conversion of glucu-
ronide methyl esters by plasma esterases is generally a fast process. In
the study by Houba et al., however, the administered dose was
suggested to saturate the esterases in plasma, resulting in a relatively
slow conversion of DOX-mGA3 to DOX-GA3. In contrast, the
administrated amount of the glucuronide ester [18F]FEAnGA-Me in
our study was approximately 5 orders of magnitude lower and
therefore far below the saturation level of plasma esterases. Indeed,
[18F]FEAnGA-Me was rapidly converted to [18F]FEAnGA, as 50%
conversion was already achieved within the ﬁrst two minutes post
injection. As a consequence, no difference in plasma AUC of [18F]
FEAnGA-Me and [18F]FEAnGA was observed, nor were differences in
the clearance half-life between both tracers observed.Table 2
Pharmacokinetic parameters of both tracers and their conversion in C6 gliomas.
Parameters [18F]FEAnGA-Me (n=7) [18F]FEAnGA (n=14)
DVLogan (mL/g) 0.61±0.06 0.50±0.04
DV2TCM (mL/g) 0.63±0.09 0.48±0.04
[HNBA]/mg tissue 0.35±0.08 0.35±0.03
⁎Pb .05 and ⁎⁎Pb .005 when compared to administered [18F]FEAnGA.
Fig. 7. Comparison of the uptake of [18F]FEAnGA-Me, [18F]FEAnGA and [18F]FEA in C6
cells in the presence or absence of esterase and/or E. coli β-GUS. Fig. 8. Correlation between distribution volume in the viable part of the tumors
calculated from a graphical model ﬁt and rate of tracer cleavage determined in tissue
homogenate, after the injection of either [18F]FEAnGA (y=0.04+0.62x, R2=0.69,
P=.0002) or [18F]FEAnGA-Me (y=0.09+0.42x, R2=0.11, P=.47).
862 I.F. Antunes et al. / Nuclear Medicine and Biology 39 (2012) 854–863Metabolite analysis indicated initially rapid conversion of [18F]
FEAnGA-Me to [18F]FEAnGA, but after 8 min the fraction of [18F]
FEAnGA in plasma stabilized. The late-phase slower conversion of
[18F]FEAnGA-Me in vivo might be attributed to initial rapid non-
speciﬁc uptake of [18F]FEAnGA-Me in tissue (as observed in vitro in
the cellular uptake experiments in C6 cells), followed by slow
redistribution of the methyl ester prodrug tracer into the circulation,
where it is converted to [18F]FEAnGA. This slow late phase conversion
of the methyl ester prodrug is in agreement with observations by
Houba et al. for DOX-mGA3.
The ex vivo biodistribution of both tracers indicated similar
uptake (SUV) in most of the peripheral organs with the exception of
the liver and kidneys, where the uptake was 3 times higher after
injection of [18F]FEAnGA-Me when compared with the uptake after
injection with [18F]FEAnGA. The uptake in inﬂamed muscle was 2
times higher after [18F]FEAnGA-Me injection in comparison with the
uptake after [18F]FEAnGA injection. However, the uptake in healthy
muscle was also 2 times higher in animals injected with [18F]
FEAnGA-Me. Thus, the ratio between inﬂamed and control muscle
for the two tracers was similar. These biodistribution results are in
agreement with what we found in vitro, where [18F]FEAnGA-Me
loses selectivity when compared to [18F]FEAnGA suggesting an
increased uptake of the less hydrophilic [18F]FEAnGA-Me in normal
tissue. Indeed, also in the pharmacokinetic analysis, no statistical
differences were found between the distribution volumes (DVT) in
tumors when injected with one or either tracer.
When injected with [18F]FEAnGA, DVT in tumors is dependent on
the [18F]FEAnGA inﬂux (from the plasma to the extracellular space)
and its conversion to [18F]FEA and HNBA in the presence of
extracellular β-GUS. After [18F]FEAnGA-Me injection the DVT in
tumors depends on both [18F]FEAnGA-Me and [18F]FEAnGA inﬂux
and the conversion of [18F]FEAnGA to [18F]FEA and HNBA. Therefore,
as expected the DVT in the viable part of the tumors correlated well
with the HNBA formation after injection of [18F]FEAnGA but did not
correlate well with the HNBA formation when injected with [18F]
FEAnGA-Me (Fig. 8).
The pharmacokinetic behavior of [18F]FEAnGA-Me is likely more
favorable in man considering the lower levels of esterase in the
human body as compared to rats which would increase the
availability of the tracer for β-GUS. However, these sustained plasma
levels of tracer would ultimately increase the background activity
and therefore decrease the contrast between background and
targeted region. Therefore, different strategies should be pursued
in order to improve the pharmacokinetics of glucuronide PET tracers,
such as PET tracers with higher turn over so that the release of theradioactive moiety is faster than the clearance of the tracer, resulting
in higher tracer uptake at the target site without increasing the
background activity.
5. Conclusion
[18F]FEAnGA-Me was labeled with [18F]ﬂuoride and has a high in
vitro stability in PBS. [18F]FEAnGA-Me proved to be a good substrate
for plasma esterase and in the presence of both esterase and E. coli β-
GUS is converted to [18F]FEA and HNBA. In contrast to our hypothesis,
administration of [18F]FEAnGA-Me did not result in a signiﬁcantly
prolonged circulation of [18F]FEAnGA in rats as compared to the direct
administration of [18F]FEAnGA. In fact, due to its lower hydrophilicity,
nonspeciﬁc uptake of [18F]FEAnGA-Me increased, resulting in a lower
target to background contrast. In addition, the 2-step prodrug
activation strategy further complicates the mode of action of this
radiopharmaceutical and thus complicates the interpretation of the
imaging results. Therefore, different strategies, such as the use of
prodrug with higher β-GUS turnover should likely be pursuit in order
to improve the pharmacokinetics and pharmacodynamics of glucu-
ronide PET tracers.
Acknowledgments
We gratefully thank Katica Stojanov and Zhila Mosheini for their
help in the C6 glioma cell studies.
References
[1] Antunes IF, Haisma HJ, Elsinga PH, Dierckx RA, de Vries EFJ. Synthesis and
evaluation of [18F]-FEAnGA as a PET Tracer for beta-glucuronidase activity.
Bioconjugate Chem 2010;21:911–20.
[2] Antunes IF, Haisma HJ, Elsinga PH, van Waarde A, Willemsen ATM, Dierckx RA, de
Vries EFJ. In vivo evaluation of 1-O-(4-(2-ﬂuoroethyl-carbamoyloxymethyl)-2-
nitrophenyl)-O-b-D-glucopyronuronate: a positron emission tomographic tracer
for imaging b-glucuronidase activity in a tumor/inﬂammation rodent model.
Molecular Imaging 2011 [in press].
[3] Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW,
Pinedo HM. Distribution and pharmacokinetics of the prodrug daunorubicin-GA3
in nude mice bearing human ovarian cancer xenografts. Biochem Pharmacol
1999;57:673–80.
[4] Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW,
Pinedo HM. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-
selective chemotherapy: distribution and efﬁcacy in experimental human ovarian
cancer. Br J Cancer 2001;84:550–7.
[5] de Graaf M, Nevalainen TJ, Scheeren HW, Pinedo HM, Haisma HJ, Boven E. A
methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-
selective chemotherapy. Biochem Pharmacol 2004;68:2273–81.
863I.F. Antunes et al. / Nuclear Medicine and Biology 39 (2012) 854–863[6] Tewson TJ. Synthesis of [18F]ﬂuoroetanidazole: a potential new tracer for imaging
hypoxia. Nucl Med Biol 1997;24:755–60.
[7] van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, de Vries EFJ.
Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inﬂammation in
a rodent model. J Nucl Med 2004;45:695–700.
[8] Van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of
sigma-ligands and metabolic PET tracers for differentiating tumor from
inﬂammation. J Nucl Med 2006;47:150–4.
[9] Krak NC, Boellaard R,, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA. Effects
of ROI deﬁnition and reconstruction method on quantitative outcome and
applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging
2005;32:294–301.
[10] Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl
Med 2007;48:932–45.[11] Buursma AR, van Dillen IJ, van Waarde A, Vaalburg W, Hospers GA, Mulder NH.
Monitoring HSVtk suicide gene therapy: the role of [(18)F]FHPG membrane
transport. Br J Cancer 2004;91:2079–85.
[12] Celen S, Deroose C, de Groot T, Chitneni SK, Gijsbers R, Debyser Z. Synthesis and
evaluation of 18F- and 11C-labeled phenyl-galactopyranosides as potential probes
for in vivo visualization of LacZ gene expression using positron emission
tomography. Bioconjug Chem 2008;19:441–9.
[13] de Vries EFJ, Buursma AR, Hospers GA, Mulder NH, Vaalburg W. Scintigraphic
imaging of HSVtk gene therapy. Curr Pharm Des 2002;8:1435–50.
[14] Fei X, Wang JQ, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Synthesis of [18F]
Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nucl
Med Biol 2004;31:1033–41.
[15] Furumoto S, Takashima K, Kubota K, Ido T, Iwata R, Fukuda H. Tumor detection using
18F-labeledmatrixmetalloproteinase-2 inhibitor. NucleicMedBiol 2003;30:119–25.
